Section 2 – Product/Company Update Remote Pharmacy announces continued nationwide availability of its compounded GLP-1 formulations, including semaglutide and tirzepatide-based treatments, for ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

British Columbia’s Health Ministry is limiting the sales of two more diabetes drugs to curb their off-label use for weight ...

Prices are falling for the popular obesity treatments semaglutide (Wegovy) and tirzepatide (Zepbound), but steady access to ...

Recently, the United States has witnessed an intense legal and commercial confrontation between major pharmaceutical ...

The Health Secretary’s 10-year plan includes proposals to bring down the cost of weight-loss drugs so more patients can get them on the NHS ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

A man taking Mounjaro as a weight loss drug has explained one of the side effects he's suffering from which 'nobody talks ...